Moleculin Biotech, Inc. (MBRX) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -81.27%, forward earnings yield 39.37%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.7 | -0.03 | 1.50 | 0.00 | - |
| 2017 | -3.5 | -0.11 | 2.02 | 0.00 | - |
| 2018 | -2.3 | 0.17 | 1.89 | 0.00 | - |
| 2019 | -2.8 | 0.10 | 2.39 | 0.00 | - |
| 2020 | -2.7 | 0.29 | 2.63 | 0.00 | - |
| 2021 | -3.1 | 0.05 | 0.63 | 0.00 | - |
| 2022 | -1.0 | -0.01 | 0.58 | 0.00 | - |
| 2023 | -0.9 | 0.87 | 0.98 | 0.00 | - |
| 2024 | -0.3 | 0.00 | 0.98 | 0.00 | - |
| 2025 | -1.2 | 0.01 | 2.61 | 0.00 | 0.27% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-35.96 | $0.00 | $-3.93M | - |
| 2017 | $-47.52 | $0.00 | $-9.81M | - |
| 2018 | $-41.26 | $0.00 | $-11.88M | - |
| 2019 | $-29.18 | $0.00 | $-13.21M | - |
| 2020 | $-22.85 | $0.00 | $-15M | - |
| 2021 | $-4.94 | $0.00 | $-8.86M | - |
| 2022 | $-14.37 | $0.00 | $-27.41M | - |
| 2023 | $-15.07 | $0.00 | $-29.77M | - |
| 2024 | $-6.32 | $0.00 | $-21.76M | - |
| 2025 | $-28.42 | $0.00 | $-33.56M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.98 | $-5.69 – $-4.26 | $71.42M | $71.42M – $71.42M | 2 |
| 2027 | $-3.84 | $-4.41 – $-3.26 | $41.96M | $41.96M – $41.96M | 2 |
| 2028 | $-3.56 | $-4.83 – $-2.28 | $87.01M | $87.01M – $87.01M | 2 |
| 2029 | $0.96 | $0.96 – $0.96 | $51.99M | $51.99M – $51.99M | 1 |
| 2030 | $5.86 | $5.86 – $5.86 | $120.37M | $120.37M – $120.37M | 1 |
